2. >>Business

Biocon Boosts Biosimilars In Australia With Sandoz Partnership

Five-Year Exclusive Marketing Deal Will Cover Indian Firm’s Trastuzumab And Bevacizumab

 
• By Dave Wallace

Biocon Biologics is seeking to bolster its biosimilars business in Australia, recently integrated after being acquired from former owner Viatris, through a deal that will see Sandoz market its Ogivri and Abevmy versions of trastuzumab and bevacizumab.

Australian flag with vial and syringe
Biocon and Sandoz have struck a biosimilars deal in Australia • Source: Shutterstock

Biocon Biologics and Sandoz have struck a marketing partnership in Australia that will see Sandoz commercialize Biocon’s Ogivri (trastuzumab) and Abevmy (bevacizumab) biosimilars.

The five-year deal will give Sandoz exclusive rights to promote, sell and distribute the trastuzumab and bevacizumab biosimilars – which Biocon said had local markets valued at AUD35m ($22.8m) and AUD45m respectively – in Australia

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Hyloris Strikes New Deals With AFT And QliniQ Over Novel Valacyclovir Formulation

 
• By Adam Zamecnik

The Belgian value-added medicines specialist company struck two commercialization deals over its novel valacyclovir oral suspension that span three continents, marking a further milestone in the product’s development.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

More from Business